NCT06816160 (TRUTH) is a clinical trial of tru-cut biopsy in Tumor, sponsored by General University Hospital, Prague.

Who is sponsoring NCT06816160?

NCT06816160 is sponsored by General University Hospital, Prague.

What drugs are being tested in NCT06816160?

Interventions in NCT06816160: tru-cut biopsy.

Is NCT06816160 still recruiting?

NCT06816160 is currently recruiting now. Last updated 10 February 2025.

Last reviewed 2025-02-10 · How we verify

NCT06816160: TRUTH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TRU-Cut Biopsy in Tumor cHaracterisation

Recruiting now Last updated 10 February 2025

What this trial tests

trial testing tru-cut biopsy in Tumor in 250 participants. Currently enrolling.

Timeline

1 February 2024

Primary endpoint
31 January 2026

31 January 2027

Quick facts

Lead sponsor	General University Hospital, Prague
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	250
Start date	1 February 2024
Primary completion	31 January 2026
Estimated completion	31 January 2027
Sites	1 location across Czechia

Drugs / interventions tested

tru-cut biopsy

Conditions studied

Tumor — all drugs for Tumor →

Sponsor

General University Hospital, Prague

Who can join

18 and older, female only, with Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tru-cut biopsy (TCB) is a minimally invasive method to get an adequate sample from the lesion in order to tailor the appropriate management avoiding unnecessary surgery. The aim of our trial is to evaluate the adequacy, accuracy and safety of the method related to the final histology as reference standard.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tumor

Currently open trials in the same condition.

NCT07399652 — Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures · NA · recruiting
NCT07382752 — Decoupling Immunotherapy Toxicity and Cancer Response · recruiting
NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
NCT07147465 — Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for On · recruiting

Other General University Hospital, Prague trials

Trials by the same sponsor.

NCT07493928 — HPV After chemoRadioTherapy · recruiting
NCT07495410 — Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT · NA · enrolling by invitation
NCT06942533 — Effect of Visual Feedback From the SpiroGym Mobile Application · NA · recruiting
NCT06789978 — Rapid Prehospital ACcess to ECPR in Prague · NA · recruiting
NCT06585332 — Handgrip and Respiratory Dysfunction in HD Patients. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06816160 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by General University Hospital, Prague
Last refreshed: 10 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06816160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing